Skip to content
OpenCapital
Get started

Exelixis EXEL AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value

AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
——
Gilead Sciences logo
Gilead SciencesGILD
——
Moderna logo
ModernaMRNA
——

Other financials

Income statement

See full
Revenue$610.8M+10.0%
Gross profit$590.9M+10.2%
Operating income$251.3M+34.5%
Net income$210.5M+31.9%
EPS (diluted)$0.79+43.6%

Balance sheet

See full
Cash & equivalents$226.2M+23.1%
Total debt$169.5M-9.4%
Total equity$1.9B-9.2%
Total assets$2.6B-8.6%

Cash flow

See full
Operating cash flow$251.8M+19.1%
CapEx$1.5M-48.9%
Free cash flow$250.3M+20.1%

Valuation

See full
Market cap$13.05B+10.1%
Enterprise value$12.99B+9.5%
P/E15.7×-2.8×
P/S5.5×+0.3×

Profitability

See full
Gross margin96.4%-0.3pp
Operating margin39.4%+6.3pp
Net margin35.1%+7.1pp
FCF margin38.6%+2.9pp

Returns & leverage

See full
Return on equity41%+10.8pp
Debt / equity0.1×0.0×
Current ratio3.3×-0.2×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's afs and trading securities - unrealized loss position (<12 months) fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exelixis's AFS and trading securities - unrealized loss position (<12 months) fair value?
Exelixis (EXEL) reported AFS and trading securities - unrealized loss position (<12 months) fair value of $480.39M in Q1 2026.
How has Exelixis's AFS and trading securities - unrealized loss position (<12 months) fair value changed year-over-year?
Exelixis's AFS and trading securities - unrealized loss position (<12 months) fair value increased by 64.0% year-over-year, from $292.88M to $480.39M.
What is the long-term trend for Exelixis's AFS and trading securities - unrealized loss position (<12 months) fair value?
Over 2 years (2023 to 2025), Exelixis's AFS and trading securities - unrealized loss position (<12 months) fair value has grown at a -62.7% compound annual growth rate (CAGR), from $419.3M to $58.2M.